NASDAQ$RDNT

Radnet Inc · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

RadNet reported record first quarter revenue and adjusted EBITDA from imaging center operations and revised upwards 2023 financial guidance ranges for revenue and adjusted EBITDA.

RadNet reported a strong first quarter with a 14.3% increase in revenue to $390.6 million and adjusted EBITDA of $48.2 million. The company has revised its 2023 guidance upwards for revenue and adjusted EBITDA, reflecting confidence in its core imaging center business and strategic initiatives.

  • Revenue from the Imaging Center reporting segment increased by 13.9% to $388.4 million.
  • Adjusted EBITDA, excluding losses from the AI reporting segment, increased by 26.2% to $52.7 million.
  • Overall volume increased 14.0% over the prior year's first quarter.
  • The company revised upwards its 2023 financial guidance ranges for revenue and adjusted EBITDA.

Headline financials

Total Revenue

$391M

Previous: $342M+14.3%
EPS (adj)

-$0.08

Previous: -$0.15+46.7%
Imaging Centers Operated

363

Previous: 351+3.4%
Capital Expenditures

-$65.6M

Previous: -$61.7M-6.3%
Free Cash Flow

-$86.6M

Previous: -$58.7M-47.5%
Net Income

-$21M

Previous: $3.01M-797.1%
Operating Income

$6.67M

Previous: -$1.72M+488.1%
Gross Profit

$38.7M

Previous: $26.7M+44.8%
Cash & Equivalents

$90.8M

Previous: $70.7M+28.5%
Total Assets

$2.41B

Previous: $2.14B+12.7%
Stock-Based Comp

$12.2M

Previous: $11.1M+9.8%

Revenue & EPS history

Radnet · Revenue · Quarterly

$391M

Q1 2023+14.3%vs Q1 2022
Beat estimate in 13 of 15 quarters(87%)
ActualEstimate

Forward guidance

RadNet has increased its guidance ranges for Revenue and Adjusted EBITDA to reflect the first quarter's strong financial results. The company is increasing its guidance levels for cash interest expense and capital expenditures to account for both the rising cost of interest and to fund the completion of certain de novo facilities.

Tailwinds

  • Opportunities to expand operations in all markets organically.
  • Opportunities to expand operations through new acquisitions.
  • Opportunities to expand operations through joint ventures.
  • Expanding roll-out of the Enhanced Breast Cancer Detection (EBCD) program.
  • Innovating new features and capabilities of AI engines for breast, lung and prostate imaging.

Headwinds

  • Economic environment.
  • Supply chain disruptions.
  • Inflation.
  • Possibility of further variants of COVID-19.
  • Rising cost of interest on debt.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

+0.8%

Avg return

Earnings day

+0.3%

Avg return

5 days after

+4.8%

Avg return

30 days after

51%

33 / 65 earnings

Positive

+22.5%

Q4 2020

Best reaction

-17.3%

Q1 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-4.1%-10.1%-0.1%
Q4 2025+7.7%-13.1%-20.8%
Q3 2025+3.4%-4.0%-1.5%
Q1 2025+2.5%+9.7%+6.4%
Q4 2024-3.7%-7.8%-14.2%
Q3 2024+19.1%+9.7%+8.8%
Q2 2024+3.7%+3.6%+5.0%
Q1 2024+2.1%+6.2%+16.7%
Q4 2023+18.2%+26.4%+29.7%
Q3 2023+0.1%-2.1%+23.0%
Q2 2023+0.6%-0.3%-5.0%
Q1 2023-1.7%-6.2%+10.1%
Q4 2022+10.8%+19.1%+16.3%
Q3 2022-5.3%-4.6%+16.7%
Q2 2022+3.5%+5.4%-2.0%
Q1 2022-5.9%-5.9%+4.9%
Q4 2021-7.1%-7.6%-9.3%
Q3 2021-8.2%-9.0%-17.5%
Q2 2021-11.7%-19.9%-21.0%
Q1 2021+3.0%+1.1%+42.5%
Q4 2020+22.5%+26.2%+15.0%
Q3 2020+13.9%+11.0%+17.6%
Q2 2020-1.1%-2.8%-12.6%
Q1 2020+4.6%+3.7%+18.8%
Q4 2019-14.2%-46.9%-32.9%
Q3 2019-2.0%+11.5%+22.4%
Q2 2019+3.1%+3.6%-4.8%
Q1 2019+4.1%+4.3%-1.2%
Q4 2018+9.8%+2.4%-5.7%
Q3 2018-7.1%-14.2%-16.9%
Q2 2018+1.1%+1.1%-1.8%
Q1 2018-2.6%-2.6%-3.0%
Q4 2017+14.0%+22.2%+39.1%
Q3 2017-3.4%-5.3%-6.8%
Q2 2017-1.2%-1.2%+37.9%
Q1 2017+1.6%+8.7%+22.2%
Q4 2016-6.1%-1.7%+2.6%
Q3 2016-2.2%-2.9%-8.1%
Q2 2016+4.4%+5.2%+17.1%
Q1 2016-6.7%
Q4 2015-15.0%
Q3 2015-0.8%
Q2 2015+12.3%
Q1 2015-17.3%
Q4 2014-12.1%
Q3 2014-12.4%
Q2 2014+21.3%
Q1 2014+22.2%
Q4 2013+20.1%
Q3 2013-10.2%
Q2 2013-5.1%
Q1 2013-8.4%
Q4 2012+3.6%
Q3 2012-10.3%
Q2 2012+4.1%
Q1 2011+1.0%
Q1 2012+1.0%
Q4 2011-2.7%
Q4 2009-2.7%
Q3 2010-11.6%
Q3 2011-11.6%
Q4 2010+10.5%
Q2 2010+10.5%
Q2 2011+10.5%
Q1 2010-2.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro